Identification

Name
Cefotaxime
Accession Number
DB00493
Description

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 455.465
Monoisotopic: 455.056939303
Chemical Formula
C16H17N5O7S2
Synonyms
  • (6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6R,7R)-3-(acetoxymethyl)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6R,7R)-3-Acetoxymethyl-7-{2-(2-amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • Cefotaxim
  • Cefotaxima
  • Céfotaxime
  • Cefotaxime
  • Cefotaximum
  • Cephotaxime
External IDs
  • CTX
  • HR 756
  • RU 24662
  • RU 24756

Pharmacology

Indication

Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.

Mechanism of action

The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.

TargetActionsOrganism
APenicillin-binding protein 1b
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2a
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 3
inhibitor
Bacillus subtilis (strain 168)
APenicillin-binding protein 1A
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
USolute carrier family 22 member 6Not AvailableHumans
USolute carrier family 22 member 8Not AvailableHumans
USolute carrier family 22 member 11Not AvailableHumans
USolute carrier family 22 member 7Not AvailableHumans
USolute carrier family 15 member 1Not AvailableHumans
USerum albuminNot AvailableHumans
UBeta-lactamaseNot AvailableAcinetobacter baumannii
USolute carrier family 15 member 2Not AvailableHumans
Absorption

Rapidly absorbed following intramuscular injection.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.

Hover over products below to view reaction partners

Route of elimination

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.

Half-life

Approximately 1 hour.

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
  • Neisseria meningitidis
  • Haemophilus influenzae
  • Neisseria gonorrhoeae
  • Escherichia coli
  • Salmonella typhi
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCefotaxime may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefotaxime.
AcarboseCefotaxime may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacCefotaxime may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefotaxime is combined with Acenocoumarol.
AcetaminophenCefotaxime may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Cefotaxime.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acetylsalicylic acid.
AclidiniumCefotaxime may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Purchasing individual compounds or compound libraries for your research?
Learn More
Product Ingredients
IngredientUNIICASInChI Key
Cefotaxime sodium258J72S7TZ64485-93-4AZZMGZXNTDTSME-REMKHYEUSA-M
International/Other Brands
Rantaksym (Ranbaxy) / Raxim (Ranbaxy) / Spinocef (Abbott) / Sporim (Pharmacare) / Talcef (Ipca)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CefotaximePowder, for solution2 g/1Intramuscular; IntravenousSteriMax Inc.2019-08-01Not applicableUS flag
CefotaximePowder, for solution1 g/1Intramuscular; IntravenousSteriMax Inc.2019-08-01Not applicableUS flag
Cefotaxime and DextroseInjection1 g/50mLIntravenousB. Braun Medical Inc.2004-08-102005-08-01US flag
Cefotaxime and DextroseInjection2 g/50mLIntravenousB. Braun Medical Inc.2004-08-102005-08-01US flag
Cefotaxime Sodium for Injection BPPowder, for solutionIntramuscular; IntravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada flag
Cefotaxime Sodium for Injection BPPowder, for solutionIntramuscular; IntravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada flag
Cefotaxime Sodium for Injection BPPowder, for solutionIntramuscular; IntravenousAurobindo Pharma Limited (Unit Vi)Not applicableNot applicableCanada flag
Cefotaxime Sodium for Injection, BPPowder, for solutionIntramuscular; IntravenousHospira Healthcare Ulc2010-07-072018-03-21Canada flag
Cefotaxime Sodium for Injection, BPPowder, for solutionIntramuscular; IntravenousSterimax Inc2015-03-12Not applicableCanada flag
Cefotaxime Sodium for Injection, BPPowder, for solutionIntramuscular; IntravenousHospira Healthcare Ulc2010-07-062018-03-21Canada flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CefotaximeInjection, powder, for solution1 g/1IntravenousHospira, Inc.2016-02-192016-02-20US flag
CefotaximeInjection, powder, for solution500 mg/1mLIntramuscular; IntravenousWockhardt2008-06-20Not applicableUS flag
CefotaximeInjection, powder, for solution2 g/1Intramuscular; IntravenousLupin Pharmaceuticals, Inc.2005-05-272018-01-25US flag
CefotaximeInjection, powder, for solution2 g/1Intramuscular; IntravenousWockhardt USA LLC.2008-06-20Not applicableUS flag
CefotaximeInjection10 g/1IntravenousWest-Ward Pharmaceuticals Corp2002-11-20Not applicableUS flag
CefotaximeInjection, powder, for solution1 g/1Intramuscular; IntravenousAurobindo Pharma2009-11-052012-01-31US flag
CefotaximeInjection, powder, for solution2 g/1Intramuscular; IntravenousPfizer Laboratories, Division of Pfizer Inc2009-11-052012-12-11US flag
CefotaximeInjection, powder, for solution1 g/1Intramuscular; IntravenousWest-Ward Pharmaceuticals Corp2002-11-20Not applicableUS flag
CefotaximeInjection, powder, for solution2 g/1mLIntramuscular; IntravenousWockhardt2008-06-20Not applicableUS flag
CefotaximeInjection, powder, for solution1 g/1Intramuscular; IntravenousLupin Pharmaceuticals, Inc.2005-05-272018-01-25US flag
Additional Data Available
  • Application Number
    Application Number
    Available for Purchase

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code
    Available for Purchase

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
CefotaximeCefotaxime sodium (1 g/1)Powder, for solutionIntramuscular; IntravenousSteriMax Inc.2019-08-01Not applicableUS flag
CefotaximeCefotaxime sodium (2 g/1)Powder, for solutionIntramuscular; IntravenousSteriMax Inc.2019-08-01Not applicableUS flag

Categories

ATC Codes
J01DD01 — Cefotaxime
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephalosporin 3'-esters. These are cephalosporins that are esterified at the 3'-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporin 3'-esters
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / 1,3-thiazines / 2-amino-1,3-thiazoles / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azetidines
show 10 more
Substituents
1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Azole
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, 1,3-thiazole, oxime O-ether (CHEBI:204928)

Chemical Identifiers

UNII
N2GI8B1GK7
CAS number
63527-52-6
InChI Key
GPRBEKHLDVQUJE-QSWIMTSFSA-N
InChI
InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1
IUPAC Name
(6R,7R)-3-[(acetyloxy)methyl]-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][[email protected]]12SCC(COC(C)=O)=C(N1C(=O)[[email protected]]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

References

Synthesis Reference

Ingolf Macher, Gerhard Widschwenter, "Production of cefotaxime and new sodium salts." U.S. Patent US5831086, issued May, 1992.

US5831086
General References
Not Available
Human Metabolome Database
HMDB0014636
KEGG Drug
D07647
KEGG Compound
C06885
PubChem Compound
5742673
PubChem Substance
46506911
ChemSpider
4674877
RxNav
2186
ChEBI
204928
ChEMBL
CHEMBL1730
ZINC
ZINC000004468780
Therapeutic Targets Database
DAP000146
PharmGKB
PA448852
PDBe Ligand
CE3
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefotaxime
AHFS Codes
  • 08:12.06.12 — Third Generation Cephalosporins
PDB Entries
3hlw / 4kot / 4pm5 / 4pm7 / 4pm9 / 5nzy / 6c79
FDA label
Download (241 KB)
MSDS
Download (38.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceCritically-ill Patients1
4CompletedTreatmentDiabetes Mellitus1
4CompletedTreatmentLiver Cirrhosis / SBP1
4CompletedTreatmentPneumonia Ventilator Associated / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentUrinary Tract Infection1
4RecruitingTreatmentInfectious Disease - Resistant Enterobacteriaceae (Diagnosis)1
4Unknown StatusTreatmentLiver Cirrhosis1
3CompletedTreatmentEmergence of Bacterial Resistance to Antibiotics1
3CompletedTreatmentSepsis1
3RecruitingPreventionIllness, Critical / Sepsis / Shock, Septic / Ventilator-associated Bacterial Pneumonia1

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Hikma farmaceutica lda
  • Wockhardt ltd
  • B braun medical inc
  • Aurobindo pharma ltd
  • Cephazone pharma llc
  • Lupin ltd
  • Orchid healthcare
  • Sanofi aventis us llc
Packagers
  • APP Pharmaceuticals
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cardinal Health
  • Hikma Pharmaceuticals
  • Hospira Inc.
  • Lupin Pharmaceuticals Inc.
  • Patheon Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Sanofi-Aventis Inc.
  • West-Ward Pharmaceuticals
  • Wockhardt Ltd.
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntramuscular; Parenteral1 G/4ML
Injection, powder, for solutionIntravenous; Parenteral2 G/10ML
Injection, powder, for solutionParenteral1 G/4ML
InjectionIntramuscular; Intravenous1 g
InjectionIntramuscular; Intravenous500 mg
Injection, powder, for solution1 g
Injection, powder, for solution250 mg
Injection, powder, for solutionParenteral0.5 g
Injection, powder, for solutionIntramuscular; Intravenous1 g
Injection, powder, for solutionIntramuscular; Parenteral500 MG/2ML
Injection, powder, for solutionIntramuscular; Parenteral1 G
Injection, powder, for solutionParenteral1 G
Injection, powder, for solution1 G/4ML
Injection, powder, for solutionIntramuscular1 G/4ML
Injection, powder, for solutionIntravenous2 G/10ML
Injection, powder, for solutionIntravenous; Parenteral1 G/4ML
Injection, powder, for solutionIntravenous; Parenteral500 MG/2ML
Powder, for solutionIntravenous2 G
InjectionIntravenous10 g/1
Injection, powder, for solution5 g
Injection, powder, for solutionIntramuscular; Intravenous1 g/1
Injection, powder, for solutionIntramuscular; Intravenous1 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous2 g/1
Injection, powder, for solutionIntramuscular; Intravenous2 g/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1mL
Injection, powder, for solutionIntramuscular; Intravenous500 MG
Injection, powder, for solutionIntramuscular; Intravenous500 mg/1
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/1
Injection, powder, for solutionIntravenous2 g/1
Powder, for solutionIntramuscular; Intravenous1 g/1
Powder, for solutionIntramuscular; Intravenous2 g/1
InjectionIntravenous1 g/50mL
InjectionIntravenous2 g/50mL
Powder, for solutionIntravenous2 g/100ml
Injection, powder, for solutionIntravenous; Parenteral1 G
Injection, powder, for solutionIntravenous; Parenteral2 G
Injection, powder, for solutionIntravenous; Parenteral250 MG
Injection, powder, for solutionIntravenous; Parenteral500 MG
Injection, powder, for solutionIntramuscular; Parenteral1000 MG/4ML
Injection, powder, for solutionIntravenous; Parenteral2000 MG/10ML
Injection, powder, for solutionParenteral1000 MG/4ML
Injection, powder, for solution
Powder, for solutionIntramuscular; Intravenous
PowderNot applicable10 kg/10kg
Injection, powder, for solution2 g
InjectionIntramuscular; Intravenous1 g/1
InjectionIntramuscular; Intravenous1 g/50mL
InjectionIntramuscular; Intravenous10 g/1
InjectionIntramuscular; Intravenous2 g/1
InjectionIntramuscular; Intravenous2 g/50mL
InjectionIntramuscular; Intravenous500 mg/1
Injection, powder, for solutionIntramuscular; Intravenous2 g
Injection, solutionIntramuscular; Intravenous0.25 g
InjectionIntramuscular; Intravenous0.5 g
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous2 g
Powder, for solutionIntravenous
Injection, powder, for solution0.5 g
Injection, solutionIntramuscular; Intravenous0.5 g
Injection, solutionIntramuscular; Intravenous1 g
InjectionIntravenous2 g
InjectionIntravenous2 gr
Injection, solutionIntramuscular; Intravenous0.5 gr
Injection, solutionIntramuscular; Intravenous2 g
Injection, powder, for solution500 mg
Injection, powder, for solutionIntravenous1 g
InjectionIntramuscular; Intravenous1 gr
Injection, powder, for solutionIntravenous2 g
Injection, powder, for solutionIntramuscular; Intravenous1000 mg
Injection0.5 g
Injection1 g
Injection2 g
Injection, powder, for solutionIntramuscular; Intravenous500 mg/2ml
InjectionIntramuscular500 mg
InjectionIntramuscular1 g
Injection, powder, for solutionIntramuscular; Intravenous1 g/4ml
Injection, powder, for solutionParenteral2 G
InjectionIntramuscular; Intravenous1000 mg
Injection, powder, for solutionParenteral250 MG/2ML
Injection, powder, for solutionParenteral500 MG/2ML
Powder, for solution1 G
Powder, for solution2 G
Injection, powder, for solutionIntramuscular1 G
Prices
Unit descriptionCostUnit
Cefotaxime sodium 10 gm vial31.43USD vial
Claforan 10 gm vial28.64USD vial
Claforan 2 g/vial20.72USD vial
Claforan 2 gm infusion btl11.76USD each
Claforan 1 g/vial10.36USD vial
Claforan 500 mg/vial6.76USD vial
Cefotaxime sodium 2 gm vial6.48USD vial
Claforan 1 gm infusion btl6.08USD each
Claforan 2 gm vial5.74USD vial
Cefotaxime sodium 1 gm vial3.24USD vial
Claforan 1 gm vial2.12USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP-0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.146 mg/mLALOGPS
logP0.14ALOGPS
logP-1.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)3.18ChemAxon
pKa (Strongest Basic)4.15ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area173.51 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.11 m3·mol-1ChemAxon
Polarizability41.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6285
Blood Brain Barrier-0.9877
Caco-2 permeable-0.761
P-glycoprotein substrateSubstrate0.7271
P-glycoprotein inhibitor INon-inhibitor0.9091
P-glycoprotein inhibitor IIInhibitor0.5397
Renal organic cation transporterNon-inhibitor0.8465
CYP450 2C9 substrateNon-substrate0.8527
CYP450 2D6 substrateNon-substrate0.8222
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8014
CYP450 2C9 inhibitorNon-inhibitor0.812
CYP450 2D6 inhibitorNon-inhibitor0.8945
CYP450 2C19 inhibitorNon-inhibitor0.7749
CYP450 3A4 inhibitorNon-inhibitor0.7505
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9174
Ames testNon AMES toxic0.8513
CarcinogenicityNon-carcinogens0.8653
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity1.7964 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9873
hERG inhibition (predictor II)Non-inhibitor0.8723
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp1b
Uniprot ID
Q7CRA4
Uniprot Name
Penicillin-binding protein 1b
Molecular Weight
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp2a
Uniprot ID
Q8DNB6
Uniprot Name
Penicillin-binding protein 2a
Molecular Weight
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Bacillus subtilis (strain 168)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Not Available
Gene Name
pbpC
Uniprot ID
P42971
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
74405.915 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Selakovitch-Chenu L, Seroude L, Sicard AM: The role of penicillin-binding protein 3 (PBP 3) in cefotaxime resistance in Streptococcus pneumoniae. Mol Gen Genet. 1993 May;239(1-2):77-80. [PubMed:8510666]
  4. Krauss J, Hakenbeck R: A mutation in the D,D-carboxypeptidase penicillin-binding protein 3 of Streptococcus pneumoniae contributes to cefotaxime resistance of the laboratory mutant C604. Antimicrob Agents Chemother. 1997 May;41(5):936-42. [PubMed:9145848]
  5. Georgopapadakou NH, Smith SA, Cimarusti CM, Sykes RB: Binding of monobactams to penicillin-binding proteins of Escherichia coli and Staphylococcus aureus: relation to antibacterial activity. Antimicrob Agents Chemother. 1983 Jan;23(1):98-104. [PubMed:6338822]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Cell wall formation.
Gene Name
pbpA
Uniprot ID
Q8DR59
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H: Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7. [PubMed:12650826]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Details
11. Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]
Kind
Protein
Organism
Acinetobacter baumannii
Pharmacological action
Unknown
General Function
Beta-lactamase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
B2ZTR6
Uniprot Name
Beta-lactamase
Molecular Weight
40542.17 Da
References
  1. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L: Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother. 2010 Aug;54(8):3484-8. doi: 10.1128/AAC.00050-10. Epub 2010 Jun 14. [PubMed:20547808]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Pedretti A, De Luca L, Marconi C, Regazzoni L, Aldini G, Vistoli G: Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping. Bioorg Med Chem. 2011 Aug 1;19(15):4544-51. doi: 10.1016/j.bmc.2011.06.027. Epub 2011 Jun 16. [PubMed:21741846]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Luckner P, Brandsch M: Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm. 2005 Jan;59(1):17-24. [PubMed:15567297]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172]
  3. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. [PubMed:12005172]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. [PubMed:11909604]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H: Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7. [PubMed:12650826]

Drug created on June 13, 2005 07:24 / Updated on November 30, 2020 13:38

Drug search 4